Trials / Unknown
UnknownNCT01994031
Dose Escalation and Pharmacokinetic Study of Paclitaxel Liposome Injection in Treating Patients With Advanced Solid Tumor After Failure From Conventional Treatments
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- Sponsor
- Nanjing Luye Sike Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the maximum tolerated dose (MTD)of paclitaxel liposome injection and to compare the pharmacokinetic characters between paclitaxel liposome injection and paclitaxel injection and to value the effectiveness for cancer treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Paclitaxel liposome injection | |
| DRUG | Paclitaxel injection |
Timeline
- Start date
- 2014-08-01
- Primary completion
- 2015-07-01
- First posted
- 2013-11-25
- Last updated
- 2014-08-27
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT01994031. Inclusion in this directory is not an endorsement.